Through sessions and Community Hubs, attendees of ACR Convergence 2021 have multiple opportunities to connect with other rheumatology professionals. Here are some helpful tips from panelists.
The Clinical Value of Antiphospholipid Antibodies in Patients with COVID-19
Gendron et al. undertook this study to investigate the prevalence and prognostic value of conventional and nonconventional antiphospholipid antibodies in patients with COVID-19.
ACR Convergence 2021: Advocacy Successes & Challenges
The ACR’s advocacy efforts over the past year have helped put critical prior authorization and step therapy legislation in front of Congress. Learn more at ACR Convergence 2021.
Business of Rheum Session to Outline What to Expect with MIPS Value Pathways
The MIPS Value Pathways will streamline federal reporting to better incentivize quality improvement. Start preparing for MVP with this session at ACR Convergence 2021.
Looking Forward to the Rheumatology MIPS Value Pathway
The field of rheumatology is leading the way in the Centers for Medicare and Medicaid Services’ new MIPS Value Pathways with rheumatology-specific quality measures and improvement activities.
Speak Up: Ask Congress to Block Medicare Reimbursement Cuts
Rheumatologists may need to downsize and restrict patient care if Congress doesn’t act to block significant cuts to Medicare reimbursement rates totaling 9.75% in 2022.
FDA Approves Cyltezo, an Interchangeable Biosimilar to Humira
On Oct. 15, the U.S. Food & Drug Administration (FDA) approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to and interchangeable with (i.e, may be substituted for) its reference product Humira (adalimumab) for Cyltezo’s approved uses. Cyltezo is the second interchangeable biosimilar…
New Supplement to The Rheumatologist Highlights Psoriatic Arthritis Advances
It feels like a long decade has passed since March 2020. At The Rheumatologist, we closed out 2020 with a special supplement on gout. Physician Editor Phil Seo, MD, MHS, kicked off that supplement with, “COVID-19. Black Lives Matter. A new gout guideline. These are some of the things 2020 ushered in. And we’re unlikely…
Minimizing Disease Activity in Psoriatic Arthritis
The use of objective, validated outcome measures to track progress in symptom control for patients with psoriatic arthritis was discussed in a session at the 2019 ACR/ARP Annual Meeting titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater insights into this topic and…
A Dematologist’s Perspective on Choosing an Anti-Psoriatic Drug
We are fortunate to have clinical practice guidelines for the management of psoriasis and psoriatic arthritis (PsA) from multiple organizations to help navigate today’s rapidly evolving therapeutic landscape. We are further fortunate to have multiple specialists to manage these conditions: rheumatologists and dermatologists. However, multiple guidelines, multiple drugs and multiple specialists can create a paradox…
- « Previous Page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- …
- 309
- Next Page »